Literature DB >> 12090361

2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.

.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12090361      PMCID： PMC1784605          DOI： 10.1155/S1064744902000029

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN： 1064-7449


× No keyword cloud information.
  102 in total

1.  Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.

Authors:  B G Yangco; J C Von Bargen; A C Moorman; S D Holmberg
Journal:  Ann Intern Med       Date:  2000-02-01       Impact factor: 25.391

2.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

Authors:  M S Sulkowski; D L Thomas; R E Chaisson; R D Moore
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

3.  CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy.

Authors:  F J Torriani; W R Freeman; J C Macdonald; M P Karavellas; D M Durand; D D Jeffrey; P R Meylan; R D Schrier
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

4.  Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy.

Authors:  V Soriano; C Dona; R Rodríguez-Rosado; P Barreiro; J González-Lahoz
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

5.  Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?

Authors:  O Kirk; J D Lundgren; C Pedersen; H Nielsen; J Gerstoft
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

6.  Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group.

Authors:  A D McNaghten; D L Hanson; J L Jones; M S Dworkin; J W Ward
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

7.  Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis.

Authors:  S M Whitcup; E Fortin; A S Lindblad; P Griffiths; J A Metcalf; M R Robinson; J Manischewitz; B Baird; C Perry; I M Kidd; T Vrabec; R T Davey; J Falloon; R E Walker; J A Kovacs; H C Lane; R B Nussenblatt; J Smith; H Masur; M A Polis
Journal:  JAMA       Date:  1999-11-03       Impact factor: 56.272

8.  Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  W M El-Sadr; W J Burman; L B Grant; J P Matts; R Hafner; L Crane; D Zeh; B Gallagher; S B Mannheimer; A Martinez; F Gordin
Journal:  N Engl J Med       Date:  2000-04-13       Impact factor: 91.245

9.  Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team.

Authors:  C A Benson; P L Williams; D L Cohn; S Becker; P Hojczyk; T Nevin; J A Korvick; L Heifets; C C Child; M M Lederman; R C Reichman; W G Powderly; G F Notario; B A Wynne; R Hafner
Journal:  J Infect Dis       Date:  2000-04-13       Impact factor: 5.226

10.  Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention.

Authors:  M Guerrero; S Kruger; A Saitoh; F Sorvillo; K J Cheng; C French; G Beall
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177
View more
  10 in total

1.  Tolerance and pharmacokinetic interactions of rifabutin and azithromycin.

Authors:  R Hafner; J Bethel; H C Standiford; S Follansbee; D L Cohn; R E Polk; L Mole; R Raasch; P Kumar; D Mushatt; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 2.  Future therapies for chronic hepatitis C.

Authors:  Noura M Dabbouseh; Donald M Jensen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

3.  Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region.

Authors:  F Pasquau; J Ena; R Sanchez; J M Cuadrado; C Amador; J Flores; C Benito; C Redondo; J Lacruz; V Abril; J Onofre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

Review 4.  The impact of HAART on HPV-related cervical disease.

Authors:  David H Adler
Journal:  Curr HIV Res       Date:  2010-10       Impact factor: 1.581

5.  Late diagnosis of HIV infection at two academic medical centers: 1994-2004.

Authors:  M Jean-Jacques; R P Walensky; W H Aaronson; Y Chang; K A Freedberg
Journal:  AIDS Care       Date:  2008-09

6.  Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapy.

Authors:  Joseph P Casazza; Michael R Betts; Brenna J Hill; Jason M Brenchley; David A Price; Daniel C Douek; Richard A Koup
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Cervical dysplasia and high-risk human papillomavirus infections among HIV-infected and HIV-uninfected adolescent females in South Africa.

Authors:  David H Adler; Melissa Wallace; Thola Bennie; Megan Mrubata; Beau Abar; Tracy L Meiring; Anna-Lise Williamson; Linda-Gail Bekker
Journal:  Infect Dis Obstet Gynecol       Date:  2014-10-20

8.  Utilization of Pap testing among women living with HIV enrolled in primary care in Baltimore, Maryland: A 10-year longitudinal study, 2005-2014.

Authors:  Sally Peprah; Jenell S Coleman; Anne F Rositch; Christopher J Vanden Bussche; Richard Moore; Gypsyamber D'Souza
Journal:  Papillomavirus Res       Date:  2018-10-25

Review 9.  The Interplay Between Thyroid Dysfunction and Kidney Disease.

Authors:  Yoko Narasaki; Peter Sohn; Connie M Rhee
Journal:  Semin Nephrol       Date:  2021-03       Impact factor: 5.299

10.  Quinone derivatives isolated from the endolichenic fungus Phialocephala fortinii are Mdr1 modulators that combat azole resistance in Candida albicans.

Authors:  Fei Xie; Wenqiang Chang; Ming Zhang; Ying Li; Wei Li; Hongzhuo Shi; Sha Zheng; Hongxiang Lou
Journal:  Sci Rep       Date:  2016-09-21       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.